TP53 and pachyonychia congenita: Thus, a gene therapy utilizing a construct which is activated mainly by mut Ras and repressed by wild-type p53 (wt p53) could be a selective gene therapy for PC, as up to 70–80% of PCs have both mut Ras and mut p53 [2].